BASELINE DEMOGRAPHICS AND CLINICAL CHARACTERISTICS FROM A PROSPECTIVE, RANDOMIZED, OPEN-LABEL STUDY OF PALIPERIDONE PALMITATE LONG-ACTING INJECTION IN SUBJECTS WITH RECENT-ONSET SCHIZOPHRENIA OR SCHIZOPHRENIFORM DISORDER

被引：0

作者：

Brown, Brianne ^{[1
]}

Turkoz, Ibrahim ^{[2
]}

Yue, Yong ^{[1
]}

Alphs, Larry ^{[1
]}

机构：

[1] Janssen Sci Affairs LLC, Titusville, NJ USA

[2] Janssen Res & Dev LLC, Raritan, NJ USA

来源：

SCHIZOPHRENIA BULLETIN | 2017年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

SA.12

引用

页码：S117 / S117

页数：1

共 50 条

[41] Safety and efficacy of long-acting risperidone in schizophrenia: A 12-week open-label study in stable patients switched from oral antipsychotic treatment
Lindenmayer, J
Eerdekens, E
Berry, S
Eerdekens, M
SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 173 - 173
[42] Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study
Tahara, Shigeyuki
Murakami, Mami
Kaneko, Tomomi
Shimatsu, Akira
ENDOCRINE JOURNAL, 2017, 64 (07) : 735 - 747
[43] EFFICACY AND SAFETY OF OLANZAPINE LONG-ACTING INJECTION IN PATIENTS WITH SCHIZOPHRENIA: A POST-HOC ANALYSIS OF A 6-YEAR, MULTINATIONAL, SINGLE-ARM, OPEN-LABEL STUDY
Anand, Ernie
Berggren, Lovisa
Toth, Agoston
McDonnell, David
SCHIZOPHRENIA RESEARCH, 2014, 153 : S291 - S291
[44] Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, open-label study in stable patients switched from typical and atypical oral antipsychotics
Cetin, M
Ebrinc, S
Basoglu, C
Semiz, UB
Gunay, H
Iyisoy, MS
Ergun, BM
Gunes, C
Sahan, A
Oguz, M
Noyan, O
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S134 - S135
[45] INSIGHT AND ITS RELATIONSHIP TO BASELINE CHARACTERISTICS OF SCHIZOPHRENIA PATIENTS RANDOMIZED TO LONG-ACTING INJECTABLE RISPERIDONE OR ORAL ATYPICAL ANTIPSYCHOTICS: RESULTS FROM THE PROACTIVE STUDY
Koola, Maju Mathew
Bustillo, J.
Lauriello, J.
SCHIZOPHRENIA BULLETIN, 2009, 35 : 360 - 361
[46] Safety and efficacy of long-acting risperidone in schizophrenia: A 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics
Lindenmayer, JP
Eerdekens, E
Berry, SA
Eerdekens, M
JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (08) : 1084 - 1089
[47] A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder
Harlin, Matthew
Yildirim, Murat
Such, Pedro
Madera-McDonough, Jessica
Jan, Michael
Jin, Na
Watkin, Suzanne
Larsen, Frank
CNS DRUGS, 2023, 37 (04) : 337 - 350
[48] A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder
Matthew Harlin
Murat Yildirim
Pedro Such
Jessica Madera-McDonough
Michael Jan
Na Jin
Suzanne Watkin
Frank Larsen
CNS Drugs, 2023, 37 : 337 - 350
[49] A prospective, multicentre, randomized, open-label comparison of a long-acting basal insulin analog glargine plus glulisine with premixed insulin in insulin naïve patients with Type 2 diabetes - A study from India
Raghavan, Arun
Nanditha, Arun
Satheesh, Krishnamoorthy
Susairaj, Priscilla
Vinitha, Ramachandran
Nair, Dhruv Rajesh
Snehalatha, Chamukuttan
Ramachandran, Ambady
PRIMARY CARE DIABETES, 2024, 18 (02) : 210 - 217
[50] A Phase 4, Single-arm, Open-label Study to Evaluate the Effectiveness and Safety of Tezepelumab in Patients With Severe Asthma, Including Underrepresented Racial and Clinical Groups: Initial Baseline Demographics and Clinical Characteristics From the PASSAGE Study
Lugogo, N. L.
Sumino, K.
Akuthota, P.
Burnette, A. F.
Mathur, S. K.
Lindsley, A. W.
Llanos, J.
Marchese, C.
Cook, B.
Martin, N.
Ambrose, C. S.
Emmanuel, B.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209

← 1 2 3 4 5 →